Woojung Bio Discloses Korea Kolmar Group Status - Confirms Weak Financials, Neutral Event
Woojung Bio, a subsidiary of Korea Kolmar group, disclosed its corporate group status. As of the last fiscal year, it had assets of 86.8B KRW, liabilities of 63.4B KRW, and equity of 23.4B KRW, resulting in a high debt ratio of 271.27%.
Despite sales of 37.6B KRW, the company recorded an operating loss of 3.9B KRW and a net loss of 5.5B KRW, with interest expenses of 2.9B KRW, indicating persistent profitability issues.
The largest shareholder group (including Chun Hee-jung, Chun Se-jung, So Kyung-hee) holds 34.39% of shares, treasury shares 0.95%, and the remaining 65.61% is held by other shareholders, maintaining stable control.
This disclosure is a routine filing due to the group's new designation, with no capital changes or shareholder return policies, thus having a neutral impact on the stock price.
[AI Summary]Woojung Bio is an R&D subsidiary within the Korea Kolmar group. While this filing highlights its weak financials (high leverage and losses), it is merely a regulatory requirement following group designation and does not constitute a material event affecting enterprise value.
KOSDAQ Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]